209 related articles for article (PubMed ID: 34193566)
1. TGM4: an immunogenic prostate-restricted antigen.
Lopez-Bujanda ZA; Obradovic A; Nirschl TR; Crowley L; Macedo R; Papachristodoulou A; O'Donnell T; Laserson U; Zarif JC; Reshef R; Yuan T; Soni MK; Antonarakis ES; Haffner MC; Larman HB; Shen MM; Muranski P; Drake CG
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34193566
[TBL] [Abstract][Full Text] [Related]
2. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
[TBL] [Abstract][Full Text] [Related]
3. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
[TBL] [Abstract][Full Text] [Related]
4. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
5. Markers of prostate region-specific epithelial identity define anatomical locations in the mouse prostate that are molecularly similar to human prostate cancers.
Thielen JL; Volzing KG; Collier LS; Green LE; Largaespada DA; Marker PC
Differentiation; 2007 Jan; 75(1):49-61. PubMed ID: 17244021
[TBL] [Abstract][Full Text] [Related]
6. Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice.
Arredouani MS; Tseng-Rogenski SS; Hollenbeck BK; Escara-Wilke J; Leander KR; Defeo-Jones D; Hwang C; Sanda MG
Prostate; 2010 Jun; 70(9):1002-11. PubMed ID: 20209643
[TBL] [Abstract][Full Text] [Related]
7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
8. Transglutaminase 4 as a prostate autoantigen in male subfertility.
Landegren N; Sharon D; Shum AK; Khan IS; Fasano KJ; Hallgren Å; Kampf C; Freyhult E; Ardesjö-Lundgren B; Alimohammadi M; Rathsman S; Ludvigsson JF; Lundh D; Motrich R; Rivero V; Fong L; Giwercman A; Gustafsson J; Perheentupa J; Husebye ES; Anderson MS; Snyder M; Kämpe O
Sci Transl Med; 2015 Jun; 7(292):292ra101. PubMed ID: 26084804
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.
Cappuccini F; Bryant R; Pollock E; Carter L; Verrill C; Hollidge J; Poulton I; Baker M; Mitton C; Baines A; Meier A; Schmidt G; Harrop R; Protheroe A; MacPherson R; Kennish S; Morgan S; Vigano S; Romero PJ; Evans T; Catto J; Hamdy F; Hill AVS; Redchenko I
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32591433
[TBL] [Abstract][Full Text] [Related]
10. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
Sinha M; Zhang L; Subudhi S; Chen B; Marquez J; Liu EV; Allaire K; Cheung A; Ng S; Nguyen C; Friedlander TW; Aggarwal R; Spitzer M; Allison JP; Small EJ; Sharma P; Fong L
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986125
[TBL] [Abstract][Full Text] [Related]
11. A Mutated Prostatic Acid Phosphatase (PAP) Peptide-Based Vaccine Induces PAP-Specific CD8
Vu PL; Vadakekolathu J; Idri S; Nicholls H; Cavaignac M; Reeder S; Khan MA; Christensen D; Pockley AG; McArdle SE
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454873
[TBL] [Abstract][Full Text] [Related]
12. Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine.
Wargowski E; Johnson LE; Eickhoff JC; Delmastro L; Staab MJ; Liu G; McNeel DG
J Immunother Cancer; 2018 Mar; 6(1):21. PubMed ID: 29534736
[TBL] [Abstract][Full Text] [Related]
13. Multi-omics Biomarker Pipeline Reveals Elevated Levels of Protein-glutamine Gamma-glutamyltransferase 4 in Seminal Plasma of Prostate Cancer Patients.
Drabovich AP; Saraon P; Drabovich M; Karakosta TD; Dimitromanolakis A; Hyndman ME; Jarvi K; Diamandis EP
Mol Cell Proteomics; 2019 Sep; 18(9):1807-1823. PubMed ID: 31249104
[TBL] [Abstract][Full Text] [Related]
14. Expansion of mouse castration-resistant intermediate prostate stem cells in vitro.
Xu Y; Mu J; Zhou Z; Leng Y; Yu Y; Song X; Liu A; Zhu H; Li J; Wang D
Stem Cell Res Ther; 2022 Jul; 13(1):299. PubMed ID: 35841025
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC).
Bilusic M; McMahon S; Madan RA; Karzai F; Tsai YT; Donahue RN; Palena C; Jochems C; Marté JL; Floudas C; Strauss J; Redman J; Abdul Sater H; Rabizadeh S; Soon-Shiong P; Schlom J; Gulley JL
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762322
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model.
Ardiani A; Farsaci B; Rogers CJ; Protter A; Guo Z; King TH; Apelian D; Hodge JW
Clin Cancer Res; 2013 Nov; 19(22):6205-18. PubMed ID: 24048332
[TBL] [Abstract][Full Text] [Related]
17. The evolving role of immunotherapy in prostate cancer.
Gerritsen WR
Ann Oncol; 2012 Sep; 23 Suppl 8():viii22-7. PubMed ID: 22918924
[TBL] [Abstract][Full Text] [Related]
18. A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy.
Daniels-Wells TR; Helguera G; Leuchter RK; Quintero R; Kozman M; Rodríguez JA; Ortiz-Sánchez E; Martínez-Maza O; Schultes BC; Nicodemus CF; Penichet ML
BMC Cancer; 2013 Apr; 13():195. PubMed ID: 23594731
[TBL] [Abstract][Full Text] [Related]
19. Personalized ex vivo multiple peptide enrichment and detection of T cells reactive to multiple tumor-associated antigens in prostate cancer patients.
Taborska P; Stakheev D; Strizova Z; Vavrova K; Podrazil M; Bartunkova J; Smrz D
Med Oncol; 2017 Sep; 34(10):173. PubMed ID: 28866803
[TBL] [Abstract][Full Text] [Related]
20. Transglutaminase-4 (Prostate Transglutaminase), a Potential Biological Factor and Clinical Indicator for the Diagnosis and Prognosis of Prostate Cancer.
Ye L; Sanders AJ; Jiang WG
Anticancer Res; 2023 Jan; 43(1):291-296. PubMed ID: 36585193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
